What the McCairn–Edogawa Protocol Actually Shows (and Doesn’t): Viral Long COVID Cure from Japan?

By Editorial Team - May 03, 2026

The McCairn Protocol (Edogawa–McCairn Protocol): Overview and Mechanistic Rationale

The McCairn Protocol (also referred to as the Edogawa–McCairn Protocol) is an experimental, two-phase treatment approach promoted by Kevin McCairn in collaboration with Edogawa Hospital.

It is primarily proposed for individuals with Long COVID and post-mRNA vaccine–associated syndromes, targeting hypothesized drivers such as persistent spike protein, amyloid-like fibrin microclots, autoantibodies, chronic inflammation, and associated vascular or neurological dysfunction.

Phase 1: Double Filtration Plasmapheresis (DFPP) / Plasma Adsorption (“Cleansing”)

Double Filtration Plasmapheresis (DFPP) is a specialized form of therapeutic apheresis currently used in parts of Asia, including Japan, for selected autoimmune, neurological, and metabolic conditions.

Procedure

Blood is withdrawn, often via a large-bore catheter (e.g., internal jugular access).
It is passed through a dual-filtration system designed to selectively remove high–molecular weight plasma components.
Unlike conventional plasmapheresis (which replaces plasma with donor plasma or albumin), DFPP filters and returns most of the patient’s own plasma while reducing targeted macromolecules.

Intended Targets (Hypothesized)

Circulating autoantibodies
Inflammatory mediators
Lipoproteins and large protein complexes
Putative amyloid fibrin aggregates (“microclots”)
Spike protein–related material (proposed but not well validated)

Proposed Goal

To reduce circulating factors that may impair microcirculation and contribute to symptoms such as fatigue, cognitive dysfunction (“brain fog”), and dysautonomia.

Phase 2: Stem Cell Growth Factors (SGF) / Cultured Supernatant (“Regeneration”)

The second phase involves administration of mesenchymal stem cell (MSC)–derived secretome, typically via intravenous infusion (and in some cases intranasal delivery).

Composition

Cytokines (e.g., IL-10)
Growth factors (e.g., VEGF, HGF, TGF-β)
Neurotrophic factors (e.g., BDNF, NGF)
Extracellular vesicles and exosomes

Importantly, no live stem cells are administered; rather, the therapy utilizes the paracrine signaling products of cultured MSCs, often derived from dental pulp (“primary tooth”) sources.

Proposed Goal

Promote endothelial and vascular repair
Modulate immune activity
Reduce inflammation
Support neurological recovery and tissue regeneration

Treatment is typically administered daily over approximately 10–14 days, either concurrently with or following DFPP.

Treatment Course and Monitoring

The full protocol is generally conducted as an outpatient program over ~2 weeks at the Japanese facility.

Pre- and post-treatment assessments may include:

Microclot analysis using Thioflavin T staining and fluorescence microscopy
Blood-based biomarker panels (non-standardized)

Some analyses are associated with laboratory networks linked to Dr. McCairn’s research activities.

Scientific Context and Hypothesis

Dr. McCairn’s work builds on prior neuroscience research and extends into investigation of:

Amyloid fibril formation
Abnormal coagulation patterns
Protein misfolding phenomena (including “prion-like” behavior, hypothesized)

The protocol is based on a broader hypothesis sometimes termed “spikeopathy”, referring to persistent biological effects attributed to SARS-CoV-2 infection or mRNA vaccination. These proposed effects include:

Microvascular dysfunction
Endothelial injury
Chronic immune activation

It should be noted that this framework remains controversial and is not widely accepted in mainstream clinical medicine.

Clinical Status

The protocol is not FDA-approved and is not part of established clinical guidelines.
Evidence to date consists primarily of:
- Case reports
- Small case series
- Patient testimonials (including reports of marked functional recovery in some severe cases)
As of 2026, no large-scale randomized controlled trials have been published.

Efforts are reportedly underway to develop IRB-approved clinical studies in the United States to evaluate safety and efficacy more rigorously.

Position Within the Field

The McCairn Protocol represents one investigational approach within a broader and evolving research landscape focused on:

Long COVID pathophysiology
Microvascular and coagulation abnormalities
Persistent inflammatory or immune-mediated mechanisms

While the biological rationale draws on emerging hypotheses, clinical validation remains limited, and the approach should be considered exploratory.

Summary

The McCairn (Edogawa–McCairn) Protocol combines:

DFPP-based blood filtration aimed at removing putative pathogenic circulating factors
MSC-derived secretome therapy intended to promote repair and immunomodulation

Although early anecdotal reports describe substantial improvements in some patients, the protocol currently remains investigational, with uncertain efficacy, unstandardized biomarkers, and limited safety data.

For the latest, check sources like Synaptek Labs or updates from involved clinicians.

Why the McCairn–Edogawa Protocol Is Trending — and What It Actually Means

Here’s a grounded breakdown.

1. The Real Driver: Visual, Emotional Proof

Platforms like X amplify before/after transformations far more than data. (x.com)

What’s happening here:

Wheelchair → running videos
“Cloudy vs clear plasma” visuals
Highly emotive captions and language

These hit three powerful triggers:

Hope (chronic illness community)
Urgency (years without solutions)
Shareability (short, visual, dramatic)

That’s why this trend is outperforming typical medical discussions.

2. The Key Patients Driving Virality

The story around individuals like:

Kevin McCairn (protocol advocate)
Patient influencers such as Lyndsey and Charles Rixey

…is functioning as de facto “case studies” in public.

But there’s a critical distinction:

Viral case ≠ clinical evidence

Even 10–20 dramatic recoveries:

Do not establish causality
Do not rule out spontaneous improvement
Do not quantify response rates

3. The “Plasma Color Change” Narrative — Misleading Signal

The orange → yellow plasma images are being interpreted as:

“toxins / spike / microclots removed”

More grounded explanation:

Plasma color varies naturally due to:
- Lipids (triglycerides)
- Bilirubin
- Hemolysis
Apheresis always alters plasma appearance

There is no validated biomarker link between:

Plasma color and
Long COVID disease burden

This is visually compelling—but scientifically weak.

4. Why This Is Spreading So Fast Now

Converging forces:

Long COVID frustration (limited effective treatments)
Post-vaccine injury communities seeking validation
Influencers + physicians amplifying simultaneously
Coordinated messaging (fundraising, media outreach)

This creates a feedback loop:

Viral video
Community amplification
More patients travel
More testimonials
Even more virality

5. The Mechanism: Still Hypothesis, Not Consensus

The protocol rests on three unproven pillars:

A. Persistent Spike Protein

Some evidence of persistence exists
Clinical relevance remains unclear

B. Microclots / Amyloid Fibrin

Not widely accepted in mainstream hematology
Measurement methods not standardized

C. “Reset + Regenerate” Model

DFPP (Double Filtration Plasmapheresis) removes “bad factors”
Secretome restores function

This is biologically plausible—but unproven as a system

6. The Missing Data (Critical)

What’s NOT shown in viral threads:

Total number treated vs improved
Non-responders
Adverse events
Duration of benefit (weeks vs months?)
Objective metrics (VO2 max, cognitive testing, etc.)

Without these, you cannot estimate:

Effect size
Risk-benefit ratio
Reproducibility

7. Risk of Selection Bias (Huge Here)

Only the best outcomes go viral.

Possible hidden realities:

Partial responders not posted
Relapses not yet visible
Patients still early post-treatment

This is known as:

Survivorship bias + social amplification bias

8. Why Experts Are Split

Supporters say:

“We’re seeing undeniable recoveries”
“Nothing else has worked at this level”

Skeptics say:

“This is uncontrolled, high-cost experimentation”
“Mechanisms are not validated”
“Risks may be underreported”

Both positions have valid points—but the data gap remains the deciding factor

9. Where This Actually Sits (2026 Reality Check)

Evidence level: Case series / anecdote
Status: Experimental
Cost: ~$20k+ plus travel
Availability: Limited (e.g., Edogawa Hospital)

This is not yet a breakthrough—it’s an early signal

10. The Most Important Insight

This trend tells you less about the protocol—and more about the market gap:

There is massive unmet demand for effective Long COVID treatments.

That’s why:

Even weak evidence can go viral
Even high-risk treatments gain traction
Even expensive overseas options fill up

Bottom Line

What you’re seeing is:

Real patients
Real suffering
Possibly real improvements

But NOT yet:

Proven mechanism
Proven efficacy
Established safety